Soliris Insurance Denied? How to Appeal Eculizumab Coverage for PNH or aHUS
Insurance denied Soliris (eculizumab) for PNH or aHUS? Learn why these rare disease denials occur, how to use FDA approval and specialist evidence, and what patient assistance programs can help.
Soliris Insurance Denied? How to Appeal Eculizumab Coverage for PNH or aHUS
Soliris (eculizumab) is a terminal complement inhibitor that was, for many years, the most expensive drug in the world, with annual costs exceeding $500,000. It is FDA-approved for four rare and life-threatening conditions: paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). For PNH and aHUS, Soliris is not merely symptom-managing — it is often life-saving, preventing hemolytic crises, thrombosis, and catastrophic renal failure.
Despite its FDA approval across these serious indications, insurance denials are common, driven primarily by the drug's cost. If your Soliris claim has been denied, here is how to fight back.
Why Insurers Deny Soliris
Cost-driven denials. At annual costs of $400,000–$600,000, Soliris triggers maximum cost-containment scrutiny at every commercial insurer. Utilization management teams may search for any clinical or administrative justification to deny coverage.
Step therapy requirements. For PNH, some insurers may require documentation of prior treatments (transfusions, anticoagulation, supportive care) before approving a complement inhibitor. For aHUS, which can progress to irreversible renal failure within days to weeks, this is particularly dangerous.
Diagnosis verification requirements. Both PNH and aHUS are rare conditions requiring specialized testing (flow cytometry for PNH clone size; ADAMTS13, genetic mutation analysis for aHUS). Insurers may deny pending confirmation of the diagnosis with specific test thresholds.
Off-label use concerns. While Soliris has four FDA-approved indications, any use outside these exact indications may be denied as off-label. Confirm the indication matches the FDA label before appeal.
Switch to Ultomiris. With the availability of Ultomiris (ravulizumab), a longer-acting complement inhibitor with the same mechanism, some insurers may require patients to use Ultomiris (which requires less frequent dosing and may be preferred by payers) rather than Soliris. If there is a clinical reason for Soliris over Ultomiris, document it clearly.
FDA Approval Status
Soliris received its initial FDA approval for PNH in March 2007 and for aHUS in September 2011. These approvals were based on Phase 3 trials demonstrating dramatic reductions in hemolysis, transfusion requirements, thrombotic events (for PNH), and renal damage (for aHUS).
Soliris holds FDA Orphan Drug Designation for PNH, aHUS, gMG, and NMOSD. In your appeal, cite the specific approved indication and Orphan Drug Designation, and emphasize that Soliris is an FDA-approved treatment for a rare, life-threatening disease — not an experimental therapy.
Building Your Appeal
Hematologist or nephrologist letter. Your specialist should document the confirmed diagnosis (with PNH clone size by flow cytometry, or aHUS diagnosis with exclusion of TTP/STEC-HUS), disease severity, prior complications (thrombosis, hemolytic crises, renal impairment), and the clinical rationale for eculizumab.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Diagnostic confirmation. For PNH: include flow cytometry results showing GPI-deficient red blood cells and/or granulocytes. For aHUS: include documentation of ADAMTS13 levels, complement mutation analysis where available, and exclusion of other TMA causes.
Phase 3 trial publications. Published results in the New England Journal of Medicine and Blood for PNH and aHUS demonstrate significant reductions in hemolysis, transfusion dependence, and renal damage. Cite these in your appeal.
Specialty society guidelines. The International PNH Interest Group and the American Society of Nephrology have published guidelines on eculizumab use for PNH and aHUS, respectively. Include relevant guideline citations.
Urgency documentation for aHUS. aHUS can cause irreversible renal damage within days. If an aHUS patient is experiencing active disease, emergency access may be needed, and the treating nephrologist should document this as a medical emergency.
Expedited Review Rights
Both PNH and aHUS can be life-threatening. Acute hemolytic crises in PNH and active thrombotic microangiopathy in aHUS constitute medical emergencies. Request expedited review immediately, with physician documentation that any delay in treatment risks irreversible renal failure, stroke, or death.
External Independent Review: Complete Guide" class="auto-link">External Review
After internal appeal denial, external review by a hematologist or nephrologist can assess whether the insurer's denial criteria are clinically justified. For a life-threatening rare disease with an FDA-approved treatment and Orphan Drug Designation, denials based on cost or step therapy are vulnerable in external review.
Patient Assistance Programs
AstraZeneca, the manufacturer of Soliris, offers the One Step patient support program, which includes insurance navigation, co-pay assistance, and a free drug program (the Alexion OneSource program) for eligible uninsured or underinsured patients. Contact them immediately upon denial — the free drug program can provide access while your appeal is pending.
NORD (National Organization for Rare Disorders) provides disease-specific financial assistance. The PNH Alliance and Aplastic Anemia and MDS International Foundation provide advocacy and peer support resources.
Fight Back With ClaimBack
Soliris denial for PNH or aHUS is not just a financial problem — it is a medical emergency in the making. ClaimBack helps patients with rare blood disorders build urgent, evidence-based insurance appeals that get to the clinical and regulatory core of why coverage cannot be denied.
Start your appeal at https://claimback.app/appeal.
Related Reading
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides